All News
Transcranial Stimulation is Effective in Fibromyalgia
A randomized, controlled clinical trial in fibromyalgia (FM) has shown the efficacy of transcranial direct current stimulation (A-tDCS) (along with exercise and pain neuroscience education [PNE]), in alleviating the pain. https://t.co/P8SKs3JNEx
Dr. John Cush RheumNow ( View Tweet)
🦵🏼💉LOSEIT study: liraglutide led to slight↑ in medial joint space width in knee OA vs placebo (0.22 vs 0.07 mm), but difference not statistically significant (p=0.17). More potent GLP-1RAs may be needed for greater improvement in structural knee OA
@RheumNow #EULAR2025 #OP0223
Mrinalini Dey DrMiniDey ( View Tweet)
GRAPPA defines :
- D2T-PsA (failed ≥3 therapies incl. ≥2 b/tsDMARDs)
- CM(complex to manage)-PsA (adds pain, comorbidity, complexity).
A needed framework to improve trial design & real-world care.
Do these definitions fit your clinic?
#OP0175 @RheumNow #EULAR2025 https://t.co/ot1bVLIYLA
Jiha Lee JihaRheum ( View Tweet)
The definition of MAS. MAS is secondary HLH. Other causes of secondary HLH are infections, malignancy and iatrogenic.
Georgin-Lavialle S @RheumNow #EULAR2025 https://t.co/CpB78JBlVJ
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Clinical Pearl's for #MAS
Infections are still the most common cause.
Next is malignancy...
Then other causes like autoimmunity..
Ask a detailed history ! Sometimes check with the family when the pt can't give history..
#EULAR2025 @RheumNow https://t.co/fepercz5Af
Bella Mehta bella_mehta ( View Tweet)
Age of onset is really important when thinking about #MAS
Primary HLH more frequent in pediatric population. But can continue to adulthood.
#EULAR2025 @RheumNow https://t.co/J7xmTiQiwr
Bella Mehta bella_mehta ( View Tweet)
MAS can be triggered by infections in VEXAS syndrome. The threshold is reached leading to a hyperinflammatory state
Georgin-Lavialle S @rheumnow #EULAR2025 https://t.co/NKLL75rOgP
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Age & dose ⬆️ infections in JAKi
Not all JAKi are created w equal risk
@RheumNow @eular_org #EULAR2015 @drdavidliew
#JAKi & #infection https://t.co/F7zLUBuzJR
Janet Pope Janetbirdope ( View Tweet)
Stabilize the pts with HLH with steroids when still trying to figure out the diagnosis of #HLH/ #MAS
Many drugs can be used...but important to balance infection risk with immunosuppression
These are critical pts. Be vigilant..
#EULAR2025 @RheumNow https://t.co/id4ae3SWtj
Links:
Bella Mehta bella_mehta ( View Tweet)
3 Fs of diagnosis of #HLH
-Fever
-Ferritin
-Falling blood count
Raising awareness is the key! Especially in rare diseases like this where the morbidity and mortality is super high!
Collaboration between specialists help
HLH networks will be helpful like this
@RheumNow #EULAR2025 https://t.co/HWbvIma3yx
Bella Mehta bella_mehta ( View Tweet)
Treatment strategies for steroid free management of #relapsingpolychondritis
56 patients from a single center
#POS0149 #EULAR2025 @RheumNow https://t.co/d4I56opS02
Bella Mehta bella_mehta ( View Tweet)
?fishing for + results #EULAR2025
⚠️opinion
be aware that results do not live or die on P values
Impt findings beyond primary endpoints may be Impt beyond P<0.05
Conversely
Unexpected P values in a database
❎interpret w caution
Consider as hypothesis only
@RheumNow
Janet Pope Janetbirdope ( View Tweet)
#HOT topic
Lung 🫁 #ultrasound for #RA #ILD
#LUS B lines vs HRCT
Single site 🇫🇷 study
V sensitive & specific
🤔needs standardization & comparison in other groups
Abst#POS-180
#EULAR2025 @RheumNow @eular_org https://t.co/PwGE4rgk40
Janet Pope Janetbirdope ( View Tweet)
In D2T-PsA (10%), 57% had persistent inflammation (PIPsA), 43% non-inflammatory (NIPsA). Ultrasound distinguished phenotypes: median US activity score 3.22 vs 0.88.,swollen joints 2.5 vs 0, tender points higher in NIPsA.
Abstract OP0176 @RheumNow #EULAR2025 https://t.co/k7m8gAzbAZ
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Difficult-to-treat & early PsA at #EULAR2025
GRAPPA definitions: D2T-PsA (≥3 therapies incl ≥2 b/tsDMARDs with persistent inflammation); C2M-PsA (broader: comorbidities, pain, intolerance). 95% GRAPPA consensus.
Abstact OP0175 @RheumNow #EULAR2025 https://t.co/eqKmMPh80x
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
▶️Erosive hand OA
🔺Gull-wing erosion @ DIPJs ✅
🔺Saw-tooth erosions @ PIPJs ✅
#OA #Osteoarthritis #EULAR2025 https://t.co/5Hh4Ki9P8V
Dr Gurdeep S Dulay gurdeep_dulay ( View Tweet)
Secukinumab Use in Refractory Giant Cell Arteritis
In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/pG3aN3o4GZ
Dr. John Cush RheumNow ( View Tweet)
1 shot will do!
#symptomatic #Knee #OA given #gene #therapy #intra-#articular
Seemed to last up to 104 weeks!
But no placebo
small safety study but sustained #WOMAC responses
Needs large #RCT but v interesting
#EULAR2025 @RheumNow @eular_org
Abst# POS0492 https://t.co/hqTqBorrbA
Links:
Janet Pope Janetbirdope ( View Tweet)
Secukinumab for PMR?
-post hoc analysis of the TitAIN study (phase 2 RCT on new onset/relapsing GCA) showed:
-Numerical reduction in patients experiencing PMR symptoms when treated with secukinumab compared to placebo.
-Safety profile was similar to the overall GCA study
Adela Castro AdelaCastro222 ( View Tweet)
Real-world study on dual bDMARD plus JAKi or TYK2i combinations in refractory PsA. 22 PsA patients on dual bDMARD + JAKi/TYK2i:
•Most common: IL-17i + TYK2i
•Total exposure: 8.5–10.5 pt-years
•Only mild URIs/stomatitis
•Clinical improvements seen in joint/skin domains https://t.co/waDReDqSDE
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
